Targeting replication stress in cancer therapy

Replication stress is a major cause of genomic instability and a crucial vulnerability of cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that coordinate the DNA damage response with cell cycle control, including ATR, CHK1, WEE1 and MYT1 checkpoint kinases. In...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Drug discovery Vol. 22; no. 1; pp. 38 - 58
Main Authors: da Costa, Alexandre André B A, Chowdhury, Dipanjan, Shapiro, Geoffrey I, D'Andrea, Alan D, Konstantinopoulos, Panagiotis A
Format: Journal Article
Language:English
Published: England Nature Publishing Group 01.01.2023
Subjects:
Cancer
Cell cycle
Cell Cycle Proteins - genetics
Cell Cycle Proteins - metabolism
Cell Cycle Proteins - therapeutic use
Checkpoint Kinase 1 - genetics
Checkpoint Kinase 1 - metabolism
Checkpoint Kinase 1 - therapeutic use
Chemotherapy
DNA Damage
DNA Replication
Humans
Immune checkpoint inhibitors
Neoplasms - drug therapy
Neoplasms - genetics
ISSN:1474-1776, 1474-1784, 1474-1784
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Replication stress is a major cause of genomic instability and a crucial vulnerability of cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that coordinate the DNA damage response with cell cycle control, including ATR, CHK1, WEE1 and MYT1 checkpoint kinases. In addition, inhibiting the DNA damage response releases DNA fragments into the cytoplasm, eliciting an innate immune response. Therefore, several ATR, CHK1, WEE1 and MYT1 inhibitors are undergoing clinical evaluation as monotherapies or in combination with chemotherapy, poly[ADP-ribose]polymerase (PARP) inhibitors, or immune checkpoint inhibitors to capitalize on high replication stress, overcome therapeutic resistance and promote effective antitumour immunity. Here, we review current and emerging approaches for targeting replication stress in cancer, from preclinical and biomarker development to clinical trial evaluation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1474-1776
1474-1784
1474-1784
DOI:10.1038/s41573-022-00558-5